Canaccord ups target on IMRIS

Canaccord Genuity has raised its price target on IMRIS (NASDAQ:IMRS; TSX:IM) to $10.50 (U.S.) from $9, saying the stock warrants a premium multiple to the small-cap med-tech peer group, given its growth profile. The stock closed at $7.31 on Monday. Analyst Jason Mills writes that IMRIS offers investors a “rare opportunity to participate in a [...]

IMRIS sells IMRIScardio to Melbourne hospital

IMRIS (TSX:IM) has sold its IMRIScardio machine to the Royal Children’s Hospital in Melbourne, Australia, making it the first paediatric hospital in the world with the capabilities of both IMRIScardio and IMRISneuro for cardiovascular procedures, an operating room for neurosurgery and a diagnostic centre. “The IMRIS system is the first solution in the world that [...]

Australia clears sale of new IMRIS devices

IMRIS (TSX:IM) has received clearance from Australia’s Therapeutic Goods Administration for the marketing of the company’s newest products, IMRISNV and IMRIScardio. IMRISNV and IMRIScardio are the first systems in the world to allow both MRI and X-ray angiography in a single suite without the need to transport the patient between modalities.  The devices have been [...]